ImpriMed is a company engaged in the development of precision cancer treatment for canines. It provides personalized drug testing services. The Company studies patients' drug responses and helps veterinary oncologists to prescribe a final treatment. In addition, it collects gene and cell information from pets' cancer cells and organizes them in a database.
|HQ||Palo Alto, US||Map|
|Employees (est.) (Mar 2020)||11|
ImpriMed total Funding
ImpriMed latest funding size
Time since last funding
|a year ago|
|Draper Associates, Sazze Partners, Plug and Play, Pear Ventures, Bon Angels Venture Partners, Draper Dragon, StartX (Stanford-StartX Fund), Ironfire Ventures, Bass Investment, Blue Bear Ventures, Murex Partners, SEMA Translink Investment|
When was ImpriMed founded?
ImpriMed was founded in 2017.
Who are ImpriMed key executives?
ImpriMed's key executives are Sungwon Lim, Hye Ryeon Lee and Jamin Koo.
How many employees does ImpriMed have?
ImpriMed has 11 employees.
Who are ImpriMed competitors?
Competitors of ImpriMed include Small Door, Vetted PetCare and Banfield Pet Hospital.
Where is ImpriMed headquarters?
ImpriMed headquarters is located at 2627 Hanover Street, Palo Alto.
Where are ImpriMed offices?
ImpriMed has offices in Palo Alto and Seoul.
How many offices does ImpriMed have?
ImpriMed has 2 offices.
Receive alerts for 300+ data fields across thousands of companies